Vivo Gene Therapy

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Summary: 
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Subscribe to Vivo Gene Therapy